anixa.com (ANIX): Rasio rega marang prakiraan pendapatan

Anixa Biosciences, Inc. (ANIX) bases its revenue on the development of oncology drugs, including breast cancer vaccines and CAR-T therapy. An innovative approach to women's health ensures the project receives regulatory support. On GURU.Markets, the projected P/S trend demonstrates a balance between capitalization and revenue expectations, where 375.70 serves as the current parameter value. However, the risks of clinical trial failure and potential secondary offerings create a threat of equity dilution.
Rincian metrik lan analitis perusahaan Anixa (ANIX)

The forward P/S ratio measures the market value of Anixa Biosciences, Inc. (ANIX) relative to expected sales volume, allowing for an assessment of the premium paid for future cash flows amid rising costs. By analyzing the forward price-to-sales ratio, investors determine the sustainability of the brand's capitalization, the value of which is based on medical professionals' trust in innovative oncology vaccines and high-precision diagnostic methods.